Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2014-04-01
- Lead Sponsor
- PD Dr. med. Matthias Dollinger
- Target Recruit Count
- 170
- Registration Number
- NCT01272557
- Locations
- 🇩🇪
Universitätsklinikum Leipzig, Leipzig, Germany
🇩🇪Klinikum Ludwigsburg, Ludwigsburg, Germany
🇩🇪Universitätsklinikum des Saarlande, Homburg/Saar, Germany
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma
- First Posted Date
- 2011-01-06
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT01271504
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Vicus Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT01265576
- Locations
- 🇺🇸
Vicus Clinical Site, Houston, Texas, United States
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
- First Posted Date
- 2010-12-21
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 35
- Registration Number
- NCT01263951
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment
- Conditions
- Interventions
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2012-11-09
- Target Recruit Count
- 41
- Registration Number
- NCT01262482
- Locations
- 🇪🇸
Hospital Sant Pau, Barcelona, Spain
🇪🇸H. Josep Trueta, Girona, Spain
🇪🇸Hospital Clinic de Barcelona, Barcelona, Spain
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Human Genome Sciences Inc., a GSK Company
- Target Recruit Count
- 101
- Registration Number
- NCT01258608
- Locations
- 🇺🇦
GSK Investigational Site, Zaporizhia, Ukraine
Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT01254890
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 334
- Registration Number
- NCT01248247
- Locations
- 🇺🇸
Yale Universtiy, New Haven, Connecticut, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 204
- Registration Number
- NCT01246986
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients
- Conditions
- Interventions
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2011-11-09
- Lead Sponsor
- Sanofi
- Registration Number
- NCT01245582
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.